irbinitinib
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00650572)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545380 ↗
Also known as
- arry-380
- arry-380
- arry-380
- irbinitinib
- irbinitinib
- ont-380
- ont-380
- ont-380
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01983501 | Phase 1 | Feb 1, 2014 | Cascadian Therapeutics Inc. |
| NCT01921335 | Phase 1 | Aug 1, 2013 | Array BioPharma, Breast Cancer Research Foundation, Harvard University |
| NCT00650572 | Phase 1 | May 1, 2008 | Array BioPharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 2 | 1 | 1 | 2008 |
| Breast Cancer Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Cascadian Therapeutics Inc. | For profit | 1 | 1 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2013 |
4 organizations
Page 1 / 1